GlassScriptPhysician profile
Diane L Rose
NPI 1053302273
$9,049.98
in general payments reported to CMS, 2019-2025
36 companies · $1,573 in 2025
The $1,573 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,489 · 2020: $780 · 2021: $909 · 2022: $1,669 · 2023: $1,076 · 2024: $1,554 · 2025: $1,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,961 · Education: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,961.12 |
| Education | $241.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,106.64 | 2020-2025 | |
| Abbvie INC. | $871.08 | 2019-2025 | Botox, Rinvoq |
| Merz North America, INC. | $570.83 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $553.09 | 2019-2025 | |
| Pfizer INC. | $494.09 | 2019-2025 | |
| Janssen Biotech, INC. | $486.85 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $431.02 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Ucb, INC. | $428.72 | 2019-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $417.41 | 2022-2025 | Sotyktu |
| Amgen INC. | $388.41 | 2020-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $348.24 | 2019-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $329.89 | 2019-2024 | Arazlo, Jublia, Cabtreo |
| Medimetriks Pharmaceuticals, INC. | $280.68 | 2019-2022 | |
| Almirall LLC | $269.51 | 2019-2022 | |
| Allergan, INC. | $249.14 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $209.37 | 2024-2025 | Daxxify |
| Leo Pharma INC. | $190.53 | 2019-2023 | Adbry |
| Vyne Pharmaceuticals INC. | $175.80 | 2020 | |
| Lilly USA, LLC | $172.25 | 2019-2023 | Olumiant, Taltz |
| Botanix Sb INC | $141.69 | 2025 | Sofdra |
| Incyte Corporation | $122.99 | 2022-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $116.64 | 2019-2025 | |
| Epi Health, LLC | $107.21 | 2019-2020 | |
| Strata Skin Sciences, INC. | $87.87 | 2023-2025 | Xtrac |
| Currax Pharmaceuticals LLC | $75.29 | 2024-2025 | Onzetra Xsail, Contrave |
| Organon LLC | $66.61 | 2025 | Vtama |
| Dermavant Sciences, INC. | $63.49 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $48.92 | 2019-2023 | Libtayo |
| Biofrontera INC. | $48.34 | 2025 | Bf-Rhodoled, Rhodoled Xl, Ameluz |
| Verrica Pharmaceuticals INC. | $46.81 | 2023 | Ycanth |
| Arcutis Biotherapeutics, INC. | $39.31 | 2023-2024 | Zoryve |
| Journey Medical Corporation | $32.93 | 2024 | |
| Taro Pharmaceuticals USA, INC. | $22.70 | 2019 | |
| Avion Pharmaceuticals | $22.07 | 2024 | NP Thyroid 60 |
| Mission Pharmacal Company | $17.06 | 2021 | |
| Celgene Corporation | $16.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.